11:09 AM EDT, 10/29/2024 (MT Newswires) -- Rallybio ( RLYB ) said Tuesday that the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency approved its applications for a phase 2 study of RLYB212 in pregnant women at higher risk of developing HPA-1a alloimmunization, which can lead to fetal and neonatal alloimmune thrombocytopenia.

With the approvals, the company said it intends to initiate screening of participants in Q4.

Rallybio ( RLYB ) said the phase 2 dose confirmation study will evaluate the safety and pharmacokinetics of RLYB212 in a total of eight pregnant women in Belgium, the Netherlands, Norway, Sweden, and the UK.

Shares of the company were up 1.9% in recent Tuesday trading.

Price: 1.06, Change: +0.02, Percent Change: +1.92